Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MGLL | Q99685 | 13/20 | 0.54 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.38 |
| ▸ | HTR2A | P28223 | 1/20 | 0.37 |
| ▸ | HTR2C | P28335 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | MMP1 | P03956 | 1/20 | 0.34 |
| ▸ | MMP2 | P08253 | 1/20 | 0.34 |
| ▸ | MMP3 | P08254 | 1/20 | 0.34 |
| ▸ | MMP9 | P14780 | 1/20 | 0.34 |
| ▸ | MMP12 | P39900 | 1/20 | 0.34 |
| ▸ | MMP13 | P45452 | 1/20 | 0.34 |
| ▸ | MMP14 | P50281 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23566792 | 0.84 | MGLL (0.56) | MGLLTSHR | |
| SCHEMBL18446417 | 0.82 | MGLL (0.46) | MGLLHTR2AHTR2CKMT2AMEN1 | |
| SCHEMBL23566785 | 0.80 | MGLL (0.52) | MGLLKMT2AALDH1A1SMN1; SMN2MMP2 | |
| SCHEMBL23566790 | 0.80 | MGLL (0.52) | MGLL | |
| SCHEMBL20399228 | 0.76 | MGLL (0.48) | MGLLSIGMAR1HTR2AHTR2CKMT2A | |
| SCHEMBL18423593 | 0.75 | MGLL (0.73) | MGLLHTR2AHTR2CKMT2AKDM4E | |
| SCHEMBL18446455 | 0.72 | PDK2 (0.39) | MGLLKMT2AMEN1 | |
| SCHEMBL20411481 | 0.71 | MGLL (1.00) | MGLL | |
| SCHEMBL23881381 | 0.69 | MGLL (0.35) | MGLL | |
| SCHEMBL18423071 | 0.69 | MGLL (0.58) | MGLL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10858373-B2 | Heterocyclic spiro compounds as MAGL inhibitors | PFIZER INC. (US) | 2020-12-08 | — | — | US | disclosed |
| US-20190292203-A1 | HETEROCYCLIC SPIRO COMPOUNDS AS MAGL INHIBITORS | PFIZER INC. (US) | 2019-09-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190292203-A1 | HETEROCYCLIC SPIRO COMPOUNDS AS MAGL INHIBITORS | MAG, MAGI3, APC | MGLL 16/4885SIGMAR1 3473/4885HTR2A 1613/4885 |
| US-10858373-B2 | Heterocyclic spiro compounds as MAGL inhibitors | MAG, MAGI3, APC | MGLL 16/4885SIGMAR1 3473/4885HTR2A 1613/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.